Interfering RNA Silences Genes in 'Slippery' Immune Cells
News May 09, 2006
A technical advance in laboratory techniques may provide biology researchers broader access to RNA interference, a process of blocking the activity of targeted genes.
Writing in the Journal of Immunological Methods, published online on March 24, a research team from The Children's Hospital of Philadelphia combined laboratory technologies in using RNA interference to manipulate human T cells.
"T cells have previously been difficult to modify with interfering RNA, being more mobile than other cell types that typically remain stationary in cell cultures," said study leader Terri H. Finkel, M.D., Ph.D., chief of Rheumatology at The Children's Hospital of Philadelphia.
"Our approach achieves results comparable to the conventional technique, which uses synthetic small interfering RNA but is very expensive and in short supply. We expect our technique to expand the toolbox for scientists doing research in immunology."
Over the past few years, biomedical researchers have been investigating how they might eventually harness RNAi in new medicines.
Another line of research uses RNAi as a research tool, investigating the functions of specific genes by studying what happens when RNAi temporarily silences them - a process calling "knocking down" the gene.
The research by Dr. Finkel's team aims to extend RNAi to a wider pool of researchers by making the technique less expensive and more widely available, as well as adapting it to T cells, a cell type previously intractable to such manipulation.
Their technique combines three technologies already accessible to lab investigators: nucleofection, siRNA expression cassettes, and siRNA expression vectors.
Nucleofection technology uses specialized solutions and electrical pulses to temporarily open a cell nucleus. Into the nucleus, researchers insert a payload of DNA.
The researchers encased the DNA within an siRNA expression cassette (SEC), a product that carries genetic sequences to regulate the gene activity that yields an siRNA.
After the researchers tested a variety of SECs to determine which is the most effective, they inserted the desired SEC into a vector, a biological agent that inserts itself into a target cell's nucleus more efficiently than an unaccompanied cassette.
The researchers first tested their approach by introducing a gene for green fluorescent protein into human T cells, and using siRNA to inhibit that gene's expression, and dim its fluorescent glow.
They then applied their approach to HALP, a gene naturally active in T cells. Dr. Finkel previously discovered and named HALP, an acronym for "HIV- associated life preserver," showing that it had a role in prolonging HIV infection by helping HIV-infected T cells survive attack by the immune system.
Using siRNA and their laboratory techniques, the investigators succeeded in "knocking down," that is, decreasing gene expression by HALP.
Because their previous research strongly suggests that HALP promotes latent HIV infection, the technique has a potential application to HIV treatment.
"The siRNA may represent a suicide vector: by knocking down HALP it may allow HIV-infected cells to self-destruct, thus eliminating a hiding place for the virus," said Dr. Finkel.
"More broadly," she added, "the technique could theoretically be directed against other immune-related diseases, by silencing harmful genes active in T cells."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.